Fundamental Analysis of ATAI LIFE SCIENCES NV(NASDAQ:ATAI) stock

Fundamental Rating

Overall ATAI gets a fundamental rating of 2 out of 10. We evaluated ATAI against 194 industry peers in the Pharmaceuticals industry. While ATAI seems to be doing ok healthwise, there are quite some concerns on its profitability. ATAI is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ATAI has reported negative net income.

In the past year ATAI has reported a negative cash flow from operations.

In the past 5 years ATAI always reported negative net income.

ATAI had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

ATAI has a worse Return On Assets (-65.11%) than 71.88% of its industry peers.

With a Return On Equity value of -88.25%, ATAI perfoms like the industry average, outperforming 42.71% of the companies in the same industry.

		Industry Rank	Sector Rank
ROA	-65.11%
ROE	-88.25%
ROIC	N/A

ROA(3y)-34.71%

ROA(5y)-55.84%

ROE(3y)-39.84%

ROE(5y)-66.13%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ATAI does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ATAI does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ATAI has about the same amount of shares outstanding.

The debt/assets ratio for ATAI is higher compared to a year ago.

2.2 Solvency

Based on the Altman-Z score of -2.93, we must say that ATAI is in the distress zone and has some risk of bankruptcy.

With a Altman-Z score value of -2.93, ATAI perfoms like the industry average, outperforming 40.63% of the companies in the same industry.

A Debt/Equity ratio of 0.14 indicates that ATAI is not too dependend on debt financing.

ATAI has a Debt to Equity ratio (0.14) which is in line with its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	0.14
Debt/FCF	N/A
Altman-Z	-2.93

ROIC/WACCN/A

WACC7%

2.3 Liquidity

ATAI has a Current Ratio of 5.81. This indicates that ATAI is financially healthy and has no problem in meeting its short term obligations.

Looking at the Current ratio, with a value of 5.81, ATAI is in the better half of the industry, outperforming 70.83% of the companies in the same industry.

ATAI has a Quick Ratio of 5.81. This indicates that ATAI is financially healthy and has no problem in meeting its short term obligations.

ATAI has a better Quick ratio (5.81) than 71.88% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	5.81
Quick Ratio	5.81

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 70.41% over the past year.

Looking at the last year, ATAI shows a decrease in Revenue. The Revenue has decreased by -2.65% in the last year.

EPS 1Y (TTM)70.41%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-165.46%

Revenue 1Y (TTM)-2.65%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-54.02%

3.2 Future

ATAI is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 67.94% yearly.

The Revenue is expected to grow by 288.68% on average over the next years. This is a very strong growth

EPS Next Y-178.45%

EPS Next 2Y-54.65%

EPS Next 3Y-34.51%

EPS Next 5Y67.94%

Revenue Next Year-2.09%

Revenue Next 2Y-18.8%

Revenue Next 3Y333.48%

Revenue Next 5Y288.68%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATAI. In the last year negative earnings were reported.

Also next year ATAI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as ATAI's earnings are expected to decrease with -34.51% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-54.65%

EPS Next 3Y-34.51%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

ATAI does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ATAI LIFE SCIENCES NV

NASDAQ:ATAI (11/22/2024, 8:24:14 PM)

After market: 1.6301 +0.02 (+1.25%)

1.61

+0.09 (+5.92%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap270.16M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-65.11%
ROE	-88.25%
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0

Health

		Industry Rank	Sector Rank
Debt/Equity	0.14
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	5.81
Quick Ratio	5.81
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

High Growth Momentum

Growth

EPS 1Y (TTM)70.41%

EPS 3YN/A

EPS 5Y

EPS Q2Q%

EPS Next Y-178.45%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-2.65%

Revenue growth 3YN/A

Revenue growth 5Y

Sales Q2Q%

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ATAI LIFE SCIENCES NV (ATAI)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens